Hints and tips:
Showing results for ARL BIO Pharma, Inc.
...Astellas Pharma bought eye-treatment specialist Iveric Bio in a $5.9bn deal in May. Mizuho splashed out $550mn for US boutique investment bank Greenhill & Co....
...Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related...
...Pfizer’s chief executive Albert Bourla said the pharma group was “deploying its financial resources to advance the battle against cancer”....
...“Thanks to their hard work, we achieved a vaccine in record time and currently have multiple vaccines available — enough to reach every corner of the globe,” said John Murphy, chief policy officer at Bio...
...In parallel, in March it announced that it would work with Translate Bio on an mRNA Covid-19 vaccine....
...This is, of course, not the first time we’ve discussed AstraZeneca, the Cambridge-based pharma group, in DD this year....
...Jeremy Levin, chair of the US biotech trade association BIO, says Mr Trump was “seemingly vindictive”, trying to harm the entire sector....
...The second drug is an antiviral in phase 2/3 clinical trials, being developed with Ridgeback Bio. It could be the first oral therapeutic, which patients would be able to take outside the hospital....
...been a political piñata in January to a recognition, at least in the minds of many policymakers, that this is an industry that we must support,” said Jeremy Levin, chairman of the industry association BIO...
...However, some companies contacted by the FT declined to join Bio’s full-throated defence of Allergan’s arrangement with the tribe, which has brought unwanted attention to the pharma industry as it tries...
...Shares in other Car-T manufacturers shot up in pre-market trading in New York, with Juno adding nearly 14 per cent and Bluebird bio up 7 per cent....
...And, at a current market cap of circa $560m, Paratek is a more-than-affordable bio-punt for Dublin-based Allergan (market cap $82bn)....
...Big pharma is enthralled....
...Trevor Jones, a veteran of the UK pharma industry, points to data that suggest up to 60 per cent of patients with depression do not take medicines as prescribed....
...Public Citizens, the liberal think tank, said leaked drafts of the order suggested “Big Pharma had captured the Trump administration”....
...Kite Pharma and Bluebird Bio fell 6 per cent in early trading....
...Shares in Kite Pharma, a rival group, fell almost 7 per cent on fears the FDA could take a broader look at the safety of Car-T and potentially suspend other studies, while Bluebird Bio dipped early before...
...In a step towards fulfilling that ambition, it signed two deals in January with biotech companies — Warp Drive Bio and Innate Pharma — worth up to €1.2bn....
...GlaxoSmithKline is developing a combination lung disease treatment, known as the “Closed Triple”, with Innoviva, a US pharma group from which the biotech spun off in 2014....
...Of the 144 companies on the Nasdaq biotech index, shares of 137 groups have fallen over the past two days, including drops of more than 15 per cent by Bluebird Bio, Ultragenyx Pharmaceutical, Horizon Pharma...
...The second proposal was that Array BioPharma would acquire both products. However, there would need to be a significant European partner to ensure the drugs’ position in the EU market....
...This month, Alexion, a rare-disease drug developer, agreed to acquire smaller rival Synageva Bio-Pharma for $8.4bn, a 139 per cent premium on its market value before the deal was announced....
...“There’s a lot of interest from both consumer goods companies and big pharma in bioprinting....
...That is propitious for some of the groups that recently completed IPOs, such as Bluebird Bio, a specialist in rare diseases, which has seen its market capitalisation surge by almost 400 per cent to $4bn...
...Surrey-based Sinclair, which in April agreed to merge with Aim-quoted IS Pharma, on Thursday agreed to pay £21m for the non-US business of dermatological specialist Advanced Bio-Technologies....
International Edition